Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in STEMI Patients Undergoing Primary PCI
IRCT20220809055645N7Phase 3Completed
- Sponsor
- Guilan University of Medical Sciences
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of empagliflozin in myocardial infarction (MI), sponsored by Guilan University of Medical Sciences. Started Mar 2024; status: completed.
02
Drugs
empagliflozin
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on IRCT20220809055645N7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220809055645N7.